- Pfizer expects to sell $32 billion of its Covid-19 shots and $22 billion of its antiviral coronavirus treatment pill Paxlovid.
- But the drugmaker posted mixed fourth-quarter results, beating on earnings but missing on revenue.
- Pfizer forecasts $98 billion to $102 billion in sales for 2022, and adjusted earnings per share of $6.35 to $6.55.
- On an unadjusted basis, fourth-quarter profit soared more than fourfold to $3.39 billion.
www.cnbc.com/2022/02/08/covid-pfizer-pfe-earnings-q4-2021.html
Views: